Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Dystrophin family DMD polynucleotide selected from SEQ ID NO:
- 1 in patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide of 15 to 30 nucleotides in length that targets and specifically hybridizes with a 15 to 30 nucleotide complementary region of a natural antisense oligonucleotide of the DMD Dystrophin family polynucleotide selected from SEQ ID NOS;
3-6;
thereby upregulating a function of and/or the expression of the Dystrophin family polynucleotide in patient cells or tissues in vivo or in vitro.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.
-
Citations
10 Claims
-
1. A method of upregulating a function of and/or the expression of a Dystrophin family DMD polynucleotide selected from SEQ ID NO:
- 1 in patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide of 15 to 30 nucleotides in length that targets and specifically hybridizes with a 15 to 30 nucleotide complementary region of a natural antisense oligonucleotide of the DMD Dystrophin family polynucleotide selected from SEQ ID NOS;
3-6;thereby upregulating a function of and/or the expression of the Dystrophin family polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 1 in patient cells or tissues in vivo or in vitro comprising;
Specification